A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes

Inclusion Criteria:

• Have Type 2 Diabetes (T2D)

• Have HbA1c ≥7.0% (≥53 mmol/mol) to ≤10.5% (≤91 mmol/mol) as determined by thecentral laboratory at screening.

• Are of stable weight (±5%) for at least 90 days prior to screening and agree to notinitiate an intensive diet or exercise program during the study with the intent ofreducing body weight other than the lifestyle and/or dietary measures for diabetestreatment.

• Have a BMI ≥23.0 kilogram/square meter (kg/m²) at screening.

Exclusion Criteria:

• Have Type 1 Diabetes (T1D).

• Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6months prior to screening, or between screening and randomization.

• Have New York Heart Association functional classification IV congestive heartfailure.

• Have had any of the following cardiovascular (CV) conditions within 60 days prior toscreening, or between screening and randomization.

• acute myocardial infarction

• cerebrovascular accident (stroke), or

• hospitalization for congestive heart failure

• Have acute or chronic hepatitis and pancreatitis